S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
BREAKING: Tiny biotech successfully treats blindness (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Forecast, Price & News

$0.69
-0.02 (-2.82%)
(As of 10/2/2023 ET)
Compare
Today's Range
$0.63
$0.71
50-Day Range
$0.56
$1.12
52-Week Range
$0.54
$16.65
Volume
82,943 shs
Average Volume
433,856 shs
Market Capitalization
$5.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

Avenue Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,537.7% Upside
$32.00 Price Target
Short Interest
Healthy
0.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.43mentions of Avenue Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$552,301 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars


ATXI stock logo

About Avenue Therapeutics (NASDAQ:ATXI) Stock

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

ATXI Price History

ATXI Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
Deadly house fire on Dodson Avenue
See More Headlines
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXI
Fax
N/A
Employees
2
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+4,537.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-3,550,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.64 per share

Miscellaneous

Free Float
8,154,000
Market Cap
$5.64 million
Optionable
Not Optionable
Beta
-0.36

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Alexandra MacLean M.D. (Age 55)
    CEO & Director
    Comp: $515.56k
  • Mr. David Jin (Age 32)
    Interim CFO, COO & Corp. Sec.
  • Dr. Lindsay Allan Rosenwald (Age 68)
    Exec. Director
  • Dr. Xiaoqin Lu M.D. (Age 48)
    Consultant
    Comp: $1.05M
  • Dr. Scott A. Reines M.D. (Age 76)
    Ph.D., Interim Chief Medical Officer
  • Mr. Srinivas Subramanian (Age 52)
    Exec. VP













ATXI Stock - Frequently Asked Questions

Should I buy or sell Avenue Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXI shares.
View ATXI analyst ratings
or view top-rated stocks.

What is Avenue Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year target prices for Avenue Therapeutics' shares. Their ATXI share price forecasts range from $32.00 to $32.00. On average, they anticipate the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 4,537.7% from the stock's current price.
View analysts price targets for ATXI
or view top-rated stocks among Wall Street analysts.

How have ATXI shares performed in 2023?

Avenue Therapeutics' stock was trading at $1.16 at the start of the year. Since then, ATXI shares have decreased by 40.5% and is now trading at $0.69.
View the best growth stocks for 2023 here
.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 26,700 shares, an increase of 184.0% from the August 31st total of 9,400 shares. Based on an average daily trading volume, of 70,100 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.5% of the company's shares are sold short.
View Avenue Therapeutics' Short Interest
.

When is Avenue Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ATXI earnings forecast
.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.52) EPS for the quarter.

When did Avenue Therapeutics' stock split?

Shares of Avenue Therapeutics reverse split before market open on Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avenue Therapeutics own?
When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $0.69.

How much money does Avenue Therapeutics make?

Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $5.64 million. The company earns $-3,550,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com.

This page (NASDAQ:ATXI) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -